GACM
KERX

Green Arrow Capital Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Green Arrow Capital Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-50,000
Closed -$505K – 340
2013
Q3 		$505K Buy
+50,000
New +$445K 0.04% 236

Other funds holding KERX

SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Green Arrow Capital Management's KERX Position: Q4 2013 in Review

Green Arrow Capital Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2013, closing a stake of 50,000 shares — an estimated $505K sold.

Green Arrow Capital Management first reported a position in KERX in Q3 2013 and held it in 1 quarter. The position peaked at $505K in Q3 2013. 124 funds tracked by Wall St. Rank hold KERX as of Q4 2013.

  • Green Arrow Capital Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2013 after selling out during the quarter.
  • Green Arrow Capital Management sold 50,000 Keryx Biopharmaceuticals Inc shares in Q4 2013, an estimated $505K.
  • Green Arrow Capital Management first reported a position in Keryx Biopharmaceuticals Inc in Q3 2013 and held it in 1 quarter.
  • Green Arrow Capital Management's Keryx Biopharmaceuticals Inc position peaked at $505K in Q3 2013.
  • 124 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2013.

Based on Green Arrow Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.